- First-line bevacizumab combined with reduced dose interferon-alpha 2a is active in patients with metastatic renal cell carcinoma2008 | Faculty of Medicine in Hradec Králové
- First-line bevacizumab combined with reduced dose interferon-alpha 2a is active in patients with metastatic renal cell carcinoma2008 | First Faculty of Medicine
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma a randomised, double-blind phase III trial2007 | First Faculty of Medicine
- Diagnostics and treatment of chronic hepatitis B +12008 | Faculty of Medicine in Hradec Králové
- Diagnostics and treatment of chronic hepatitis B +12008 | Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Diagnostics and treatment of chronic hepatitis B +12008 | First Faculty of Medicine